| 36 | 0 | 25 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨SOX10的表达与三阴性乳腺癌(TNBC)的临床病理特征以及肿瘤间质中CD8+T细胞浸润之间的关系，阐明SOX10在TNBC中的表达及作用。方法 收集2018年1月1日—2024年5月30日兰州市第一人民医院术后诊断为非特殊型浸润性乳腺癌手术标本85例，其中TNBC 45例。通过免疫组织化学染色技术，检测癌组织中SOX10、细胞角蛋白、表皮生长因子受体的表达情况，以及肿瘤间质中CD8的表达水平；利用TIMER数据库，分析SOX10基因与基底样乳腺癌的纯度以及肿瘤间质中CD8+T细胞浸润之间的关系。结果SOX10仅在TNBC组织中表达，表达率为60%(27/45)，而在所有非三阴性浸润性导管癌组织中不表达(P<0.001)，在TNBC中的SOX10表达与患者的年龄呈相关性(P<0.05)，但与病理分级、TNM分期、肿瘤的最大直径以及淋巴结转移情况无关(P>0.05)。SOX10阳性的TNBC中，基底样乳腺癌占比81.48%(22/27)。与SOX10阴性的TNBC比较，SOX10阳性的TNBC肿瘤间质中CD8+T细胞的浸润数量明显减少。结论SOX10是鉴别诊断TNBC的敏感标志物，倾向于年轻患者的癌组织中表达；SOX10阳性的TNBC肿瘤组织很可能主要源自乳腺的基底细胞，SOX10可抑制CD8+T细胞在TNBC肿瘤间质中的浸润。
Abstract：Objective To elucidate the expression and significance of SOX10 in triple-negative breast cancer(TNBC),this study investigated the relationship between SOX10 expression and the clinicopathological features of TNBC as well as the infiltration of CD8+T cells in the tumor stroma.Method We collected 85 breast cancer surgical specimens diagnosed as non-specific invasive ductal carcinoma in The First People's Hospital of Lanzhou City from January 1,2018 to May 30,2024,postoperatively,including 45 cases of TNBC.Using the immunohistochemical staining techniques,we examined the expression of SOX10,cytokeratin5/6,epidermal growth factor receptor in the cancerous tissues,and the expression level of CD8 in the tumor stroma.Furthermore,by utilizing the TIMER database,we analyzed the relationship between SOX10 gene expression and the purity of basal-like breast cancer,as well as the infiltration of CD8+T cells in the tumor stroma.Result SOX10 was exclusively expressed in triple-negative breast cancer (TNBC) tissues,with no expression observed in all non-triple-negative invasive ductal carcinoma tissues.The expression rate of SOX10 in TNBCwas 60%(27/45).The expression of SOX10 in TNBC was correlated with the ages of patients(P<0.05),but not related to the pathological grade,TNM stage,the maximum diameter of the tumor,or the status of lymph node metastasis.In SOX10-expressing TNBC,the proportion of basal-like breast cancer was as high as 81.48%(22/27).Compared with TNBC that did not express SOX10,the number of CD8+T cell infiltration in the tumor stroma of SOX10-expressing TNBC was significantly reduced.Conclusion SOX10 is a sensitive marker for differential diagnosis of TNBC,and tends to express in the cancer tissues of younger patients.In addition,the tumor tissues of SOX10-expressing TNBC are likely to mainly originate from the basal cells of the breast,and the expression of SOX10 may inhibit the infiltration of CD8+T cells in the TNBC tumor stroma.
[1]韦琳誉，邓渊韬，赵惠敏，等.香菇多糖联合紫杉醇通过FGF1/FGFR1抑制乳腺癌细胞的增殖及侵袭转移[J].兰州大学学报（医学版），2023,49(12):13-21.
[2] BANDO Y,KOBAYASHI T,MIYAKAMI Y,et al.Triple-negative breast cancer and basal-like subtype:pathology and targeted therapy[J]. The journal of medical investigation,2021,68(3/4):213-219.
[3] DERAKHSHAN F,REIS-FILHO J S. Pathogenesis of triple-negative breast cancer[J]. Annual review of pathology:mechanisms of disease,2022,17(1):181-204.
[4] LEON-FERRE R A,GOETZ M P. Advances in systemic therapies for triple negative breast cancer[J]. British medical journal,2023,381:e071674.
[5]辛颖，刘胜. LHRH受体：治疗三阴性乳腺癌的潜在靶点[J].兰州大学学报（医学版），2020,46(6):56-61.
[6] CHAPDELAINE A G,SUN G Q. Challenges and opportunities in developing targeted therapies for triple negative breast cancer[J]. Biomolecules,2023,13(8):1207-1227.
[7] BAHMAD H F,THIRAVIALINGAM A,SRIGANESHAN K,et al. Clinical significance of SOX10 expression in human pathology[J]. Current issues in molecular biology,2023,45(12):10131-10158.
[8] JAMIDI S K,HU J T,APHIVATANASIRI C,et al. Sryrelated high-mobility-group/HMG box 10(SOX10)as a sensitive marker for triple-negative breast cancer[J].Histopathology,2020,77(6):936-948.
[9]刘建兰，陈黛诗，成志强，等. SOX10和GATA3在乳腺癌中的表达及意义[J].中华病理学杂志，2022,51(6):536-541.
[10] KRIEGSMANN K,FLECHTENMACHER C,HEIL J,et al. Immunohistological expression of SOX-10 in triple-negative breast cancer:a descriptive analysis of113 samples[J]. International journal of molecular sciences,2020,21(17):6407-6417.
[11] YOON E C,WILSON P,ZUO T. et al. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers[J]. Human pathology,2020,102:13-22.
[12] JIN L F,QIN C L,QI X W,et al. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma[J]. Translational cancer research,2020,9(9):5603-5613.
[13] FENG W,LIU S H,ZHU R X, et al. SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells[J]. Biochemical and biophysical research communications,2017,485(2):522-528.
[14] LIU Y,GUO W J. SOX factors as cell-state regulators in the mammary gland and breast cancer[J]. Seminars in cell and developmental biology,2021,114:126-133.
[15] YANG K,YUN F,SHI L,et al. SOX10 promotes the malignant biological behavior of basal-like breast cancer cells by regulating EMT process[J]. Heliyon,2023,9(12):e23162.
[16] SAUNUS J M,DE LUCA X M, NORTHWOOD K,et al. Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer[J].NPJ breast cancer,2022,8(1):57-73.
[17] PURWIN T J,CAKSA S,SACAN A,et al. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas[J]. Iscience,2023,26(9):107472-107492.
[18]王雅娟，王媛，任新瑜.三阴性乳腺癌患者CD117、DOG1表达水平与临床病理特征及预后的相关性[J].协和医学杂志，2024,15(3):616-623.
[19] LI T W,FAN J Y,WANG B B, et al. TIMER:a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer research,2017,77(21):e108-e110.
[20] WANG Z, LIU L, LI Y, et al. Analysis of CK5/6 and EGFR and its effect on prognosis of triple negative breast cancer[J]. Frontiers in oncology,2021,10:575317-575327.
[21] YOON E C,WANG G,PARKINSON B,et al. TRPS1,GATA3,and SOX10 expression in triple-negative breast carcinoma[J]. Human pathology,2022,125:97-107.
[22] NA K,WOO H Y,DO S I,et al. Combination of GATA3,SOX-10,and PAX8 in a comprehensive panel to diagnose breast cancer metastases[J]. In Vivo,2022,36(1):473-481.
[23] CIMINO-MATHEWS A,SUBHAWONG A P,ELWOOD H,et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas[J]. Human pathology,2013,44(6):959-965.
[24] HSU S N,HUI E W E,LIU M Z,et al. Revealing nuclear receptor hub modules from basal-like breast cancer expression networks[J]. PLoS One,2021,16(6):e0252901.
[25] ROSENBAUM S R,CAKSA S,STEFANSKI C D,et al. SOX10 loss sensitizes melanoma cells to cytokinemediated inflammatory cell death[J]. Molecular cancer research,2024,22(2):209-220.
[26] TARIQ M U,SIDDIQUI M A,DIN N U,et al. Role of SOX10 immunohistochemical expression in diagnosing triple negative breast cancer and its correlation with clinicopathological features[J]. Cureus,2024,16(4):e59276.
[27] SIMULA L,FUMAGALLI M,VIMEUX L,et al. Mitochondrial metabolism sustains CD8+T cell migration for an efficient infiltration into solid tumors[J]. Nature communications,2024,15(1):2203-2226.
基本信息:
DOI：10.13885/j.issn.1000-2812.2025.03.002
中图分类号:R737.9
引用信息:
[1]陈宝强,李东海,郝婷等.SOX10在三阴性乳腺癌中的表达及其与肿瘤免疫浸润特征的相关性[J].兰州大学学报(医学版),2025,51(03):8-13.DOI:10.13885/j.issn.1000-2812.2025.03.002.
基金信息:
甘肃省自然科学基金资助项目（22JR5RA1063）